Monday, 11 April 2016

Metabolic pathway activates cell signaling protein to promote breast cancer metastasis

I’ve never actually been a large follower of any person that forces you to believe a specific method about a topic. This is especially true in the areas of fitness, health and wellness, weight-loss and so forth. That’s why it’s constantly great to take the important things you read on the internet with a grain of salt. Yet it’s still excellent to read as much as you could so you can absorb various viewpoints. That’s why you will see a bunch of different sorts of posts and also opinons on this blog site. I attempt to share things that I discover fascinating. It’s up to you as a specific, nevertheless to actually determine if you can think it or otherwise. Take the short article here, for instance. Some will certainly agree as well as some will certainly differ. Some will certainly enjoy, others worried or dissatisfied. Yet you need to see to it you’re investigating beyond the headline, or solitary book on this web site or that site. What are your ideas on exactly what I’ve shared below? Let me recognize if the comments.

A metabolic pathway that is up-regulated in certain breast cancers promotes the disease’s progression by activating a cell signaling protein called Arf6, according to a paper published in the Journal of Cell Biology. The study, “P53- and mevalonate pathway-driven malignancies require Arf6 for metastasis and drug resistance” by Ari Hashimoto and colleagues, has been published online ahead of print and suggests that statin-like drugs may be effective treatments for breast cancer patients whose tumors express high levels of Arf6 signaling proteins.

The mevalonate pathway (MVP) is a metabolic pathway that produces the building blocks for a wide range of biological molecules, from cholesterol to the long-chain lipid groups that anchor certain proteins to cell membranes. Mutations in the tumor suppressor p53 can up-regulate the MVP, a phenomenon that enhances the invasiveness of some, but not all, breast cancer cell lines. A team led by Hisataka Sabe at Hokkaido University Graduate School of Medicine in Sapporo, Japan, suspected that the MVP might promote invasiveness by activating the Arf6 signaling pathway, which enhances cancer cell invasion and metastasis by promoting the cells’ transition to a more motile state.

Related Stories

Ari Hashimoto and colleagues found that the MVP promotes the recruitment of Arf6 to the plasma membrane, where it can be activated by receptor tyrosine kinases. The pathway does this by generating a lipid group that anchors a protein called Rab11b here to cell membranes, allowing Rab11b to deliver Arf6 to its site of activation. Inhibiting Rab11b reduced the invasiveness of a breast cancer cell line, called MDA-MB-231, that expresses high amounts of Arf6 signaling proteins, the researchers discovered.

The Arf6 pathway may also boost the drug resistance of breast cancer cells, and Hashimoto et al. found that inhibiting Rab11b, or a component of the Arf6 pathway called EPB41L5, increased the sensitivity of MDA-MB-231 cells to two different cytotoxic compounds.

Statins inhibit the enzyme HMG-CoA reductase, one of the MVP’s key components. Originally developed to lower cholesterol levels, statins have also been investigated as potential anti-cancer drugs, but clinical trials have so far produced mixed results. Hashimoto et al.’s data suggest that future efforts might focus on breast cancer patients whose tumors express high levels of Arf6 signaling proteins, and which could therefore be susceptible to drugs that reduce the activity of Rab11b. Indeed, the researchers found that simvastatin increased the drug sensitivity of MDA-MB-231 cells and inhibited the cells’ ability to metastasize when injected into mice. “Blocking the MVP might effectively kill cancer cells that overexpress the Arf6 pathway, especially in combination with other drugs,” Sabe says. Developing this therapeutic approach could be crucial because the researchers found that patients whose tumors expressed high levels of both MVP components and Arf6 signaling proteins showed poor long-term survival rates.

Rockefeller University Press

I’ve never truly been a huge fan of anybody who forces you to think a specific method regarding a subject. This is specifically true in the locations of health and fitness, wellness, weight-loss and so forth. That’s why it’s always great to take the things you check out on the internet with a grain of salt. However it’s still great to check out as long as you can so you could soak up various points of view. That’s why you will certainly see a great deal of different kinds of write-ups and opinons on this blog. I attempt to discuss points that I locate appealing. It’s up to you as an individual, nonetheless to actually make a decision if you can think it or not. Take the write-up below, as an example. Some will certainly concur and some will differ. Some will certainly be delighted, others anxious or dissatisfied. Yet you need to make certain you’re investigating past the heading, or single post on this web site or that website. Exactly what are your ideas on just what I’ve discussed below? Let me recognize if the comments.

The post Metabolic pathway activates cell signaling protein to promote breast cancer metastasis appeared first on The VenusFactor.Reviews Weight Loss Blog.

from The VenusFactor.Reviews Weight Loss Blog - Original Post

No comments:

Post a Comment